Evidence map›Paper›PMID 39422764›Full record

Trial reportJournal of cancer research and clinical oncology2024

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.

Dayang Wang, Jiubing Zhang, Chaojie Bu, Guanzheng Liu, Guangzhong Guo, Ziyue Zhang, Guangming Lv, Zhiyuan Sheng, Zhaoyue Yan, Yvshuai Gao and 6 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05502991 (Phase 2 Study to Evaluate the Clinical Efficacy and Safety of Sintilimab Plus Low-dose Bevacizumab in Patients With Glioblastoma of Different Relapse Stages), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05502991 phase2not yet recruitingnot on this map

Phase 2 Study to Evaluate the Clinical Efficacy and Safety of Sintilimab Plus Low-dose Bevacizumab in Patients With Glioblastoma of Different Relapse Stages

TypeinterventionalSponsorHenan Provincial People's HospitalRan2022 to 2027Enrolled60ConditionsGlioblastomaArmsTislelizumab plus Bevacizumab
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Current Status and Evolution of Immunotherapy in Glioma Management.International journal of medical sciences · 2026
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dayang WangDepartment of Neurosurgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Jiubing ZhangDepartment of Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Chaojie BuPrecision Diagnosis and Treatment Engineering Research Center for Glioma Henan Province, Zhengzhou, China.
Guanzheng LiuDepartment of Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Guangzhong GuoDepartment of Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Ziyue ZhangDepartment of Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Guangming LvDepartment of Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Zhiyuan ShengDepartment of Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Zhaoyue YanDepartment of Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Yvshuai GaoDepartment of Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Meiyun WangDepartment of Radiology, Henan Provincial People's Hospital, Zhengzhou, China.
Gang LiuDepartment of Center for Clinical Single Cell Biomedicine, Department of Oncology, Clinical Research Center, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
Ruijiao ZhaoDepartment of Pathology, Henan Provincial People's Hospital, Zhengzhou, China.
Tianxiao LiDepartment of Neurosurgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Chunxiao MaDepartment of Neurosurgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Xingyao BuDepartment of Neurosurgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China. xingyaob@zzu.edu.cn.

Funding

Natural Science Foundation of Henan Province 232300421171Research Foundation of the National Health Commission of China SBGJ20232006
6 · The paper itself

Abstract

purposeImmune checkpoint blockade (ICB) therapies have shown efficacy in various tumors, but long-term responses in glioblastoma are less than 10%. Quantifying tumor in situ fluid circulating tumor DNA (TISF-ctDNA) and therapeutic dynamics may enable real-time GBM disease burden evaluation. This study explores the potential of tumor in situ fluid circulating tumor DNA (TISF-ctDNA) dynamics in predicting treatment efficacy.

methodsTISF and peripheral blood samples were collected from patients with recurrent glioblastoma (rGBM) undergoing tislelizumab (a programmed death 1 inhibitor) combined with low-dose bevacizumab (an anti-vascular endothelial growth factor antibody) treatment before and during each immunotherapy cycle. Biomarkers evaluated included TISF-ctDNA, measured using Next Generation Sequencing (NGS), and host inflammation markers such as the platelet-to-lymphocyte ratio (PLR).

resultsAll 32 patients received tislelizumab plus low-dose bevacizumab regularly. The median progression-free survival (PFS) was 4.0 months, and overall survival (OS) was 22.3 months. An analysis of 19 patients with continuous evaluable TISF showed baseline TISF-ctDNA abundance did not correlate with OS (p = 0.23) or PFS (p = 0.23). However, a change in TISF-ctDNA maximal Somatic Variant Allelic Frequency (MVAF) after six treatment cycles predicted both PFS (p = 0.02) and OS (p < 0.0001). Lower baseline PLR also correlated with better survival outcomes.

conclusionThe combination of tislelizumab and low-dose bevacizumab therapy appears to be effective in extending both OS and PFS in rGBM patients. Continuous TISF-ctDNA testing shows potential utility in complementing radiological monitoring. The temporal change pattern of TISF MVAF is more predictive of immunotherapy response than imaging. PLR before immunotherapy can screen patients likely to benefit from tislelizumab plus low-dose bevacizumab therapy.

trial registrationThe trial registration number: NCT05502991; Date of registration: 2022-08-14.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabBrain NeoplasmsCirculating Tumor DNAGlioblastomaImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalAdultAgedAntibodies, Monoclonal, HumanizedBiomarkers, TumorFemaleHumansMaleMiddle AgedTreatment OutcomeAntibodies, Monoclonal, HumanizedBevacizumabBiomarkers, TumorCirculating Tumor DNAImmune Checkpoint InhibitorstislelizumabCirculating tumor DNAImmune checkpoint blockadeRecurrent glioblastomaTumor in situ fluid

Identifiers

PMID39422764
PMCPMC11489198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.